Michael Beaubaire
Direktor/Vorstandsmitglied bei Erad Therapeutics, Inc.
Profil
Michael Beaubaire is currently a director at Erad Therapeutics, Inc. He was previously the Chairman-Scientific Advisory Board at Lincoln Park Capital LLC from 2011 to 2018.
He also served as a director at Applied BioSciences Corp.
Dr. Beaubaire holds a doctorate degree from Northwestern University and undergraduate degrees from The Wharton School of the University of Pennsylvania and The College of Arts & Sciences.
Aktive Positionen von Michael Beaubaire
Unternehmen | Position | Beginn |
---|---|---|
Erad Therapeutics, Inc. | Direktor/Vorstandsmitglied | 01.05.2016 |
Ehemalige bekannte Positionen von Michael Beaubaire
Unternehmen | Position | Ende |
---|---|---|
Lincoln Park Capital LLC
Lincoln Park Capital LLC Investment ManagersFinance Lincoln Park Capital LLC (Lincoln Park Capital) is a private equity/venture capital firm founded in 2010 by Joshua B. Scheinfeld, Jonatham I.Cope, Richard C. Vogel and Robert A. Garcia. The firm is headquartered in Chicago, Illinois. | Private Equity Investor | 28.02.2018 |
APPLIED BIOSCIENCES CORP. | Direktor/Vorstandsmitglied | - |
Ausbildung von Michael Beaubaire
Northwestern University | Doctorate Degree |
The College of Arts & Sciences | Undergraduate Degree |
The Wharton School of the University of Pennsylvania | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
APPLIED BIOSCIENCES CORP. | Health Technology |
Private Unternehmen | 2 |
---|---|
Lincoln Park Capital LLC
Lincoln Park Capital LLC Investment ManagersFinance Lincoln Park Capital LLC (Lincoln Park Capital) is a private equity/venture capital firm founded in 2010 by Joshua B. Scheinfeld, Jonatham I.Cope, Richard C. Vogel and Robert A. Garcia. The firm is headquartered in Chicago, Illinois. | Finance |
Erad Therapeutics, Inc. |